EU exports to the US reached $605.8 billion in 2024, according to the US Census Bureau. Pharmaceutical companies are ...

The job losses at the CDC are part of a broader reduction of about 5,200 positions across other government public health ...

As the Q4 2024 pharma earnings period rolls on through the first month of President Donald Trump’s second term, executives ...

Q4 2024 Earnings Conference Call February 7, 2025 3:00 AM ETCompany ParticipantsNicolas Hieronimus - CEOChristophe Babule ...

Market report delivers crucial insights into the market's growth trajectory and the primary revenue drivers anticipated ...

Sanofi January 27, 2025 The Trump administration's Interior Department said on Friday it had officially changed the name of the Gulf of Mexico to the Gulf of America, and the Alaskan peak Denali ...

META_DESC_INVESTMENT_IDEA ...

Trump ordered his administration on Thursday to consider imposing reciprocal tariffs on a country-by-country basis ...

Review of data from the trial found that the vaccine was not sufficiently effective at preventing invasive E coli disease ...

Immune checkpoint blockers (ICBs) have revolutionized the treatment of non–small cell lung cancer (NSCLC). Currently, one-dose-fits-all maximalist regimens have been considered the standard of care, ...

Armed with positive data from a phase 2b trial, Teva and Sanofi have decided to push their anti-TL1A antibody duvakitug into a phase 3 programme in inflammatory bowel disease (IBD). The results of ...

Sanofi has moved ahead with plans to challenge Pfizer and MSD for a piece of the market for pneumococcal vaccines, taking a 21-valent shot licensed from SK Biosciences into phase 3 testing.